T
Tevogen Bio Holdings Inc. (TVGN)
NGM – Real vaqt narxi. Valyuta: USD
6.97
-0.11 (-1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
6.97
-0.11 (-1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Tevogen Bio Holdings Inc. klinik tadqiqot bosqichidagi ixtisoslashgan immunoterapiya kompaniyasi bo'lib, yuqumli kasalliklar, saraton va boshqa kasalliklarni davolash uchun tayyor, aniq T-hujayrali terapiyalarni ishlab chiqadi. Kompaniya TVGN 489ni ishlab chiqadi, bu ambulatory yuqori xavfli kattalar COVID-19 bemorlarini davolash bo'yicha 1-bosqich klinik sinovini yakunlagan; va B-hujayrali saraton immunokompromissiyasi bilan o'tkir SARS-CoV-2 bemorlarini davolash bo'yicha 1-bosqich klinik sinovida, shuningdek, B-hujayrali saraton ko'rsatkichlari bilan B-hujayrali immunitet tanqisligi bo'lgan boshqa o'tkir SARS-CoV-2 bemorlarini, shuningdek, Long COVIDni oldini olish va davolashni davom ettirmoqda. Shuningdek, u bachadon bo'yni saratonini davolash bo'yicha preklinik sinovda bo'lgan TVGN 920; orofarengeal saratonni davolash bo'yicha preklinik sinovda bo'lgan TVGN 960; ko'p sklerozni davolash bo'yicha preklinik sinovda bo'lgan TVGN 601; Ebsteyn-Barr virusi bilan bog'liq limfomalarni davolash bo'yicha preklinik sinovda bo'lgan TVGN 930; va gepatit B ni nishonga olgan va preklinik sinovda bo'lgan mahsulot nomzodi TVGN 116ni ishlab chiqmoqda. Tevogen Bio Holdings Inc. ilgari Tevogen Bio Inc. nomi bilan tanilgan va 2024 yil fevral oyida Tevogen Bio Holdings Inc. nomini o'zgartirgan. Kompaniya 2020 yilda tashkil etilgan va uning shtab-kvartirasi Nyu-Jersi shtatining Uorren shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
| Dr. Ryan H. Saadi M.D., M.P.H. | Co-Founder, CEO & Chairperson |
| Mr. David E. Banko CPA | Global Head of Government Affairs & Patient Access |
| Mr. Kirti Desai CPA | Chief Financial Officer |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer & Interim Head of Tevogen Generics |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-K/A | form10-ka.htm |
| 2026-04-22 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |
| 2026-03-04 | 8-K | form8-k.htm |
| 2026-02-25 | 8-K | form8-k.htm |
| 2026-01-30 | 8-K | form8-k.htm |
| 2026-01-26 | DEF 14A | formdef14a.htm |
| 2026-01-16 | PRE 14A | formpre14a.htm |
| 2025-09-26 | 8-K | form8-k.htm |
| 2025-08-14 | 10-Q | form10-q.htm |